Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

EXecutive Registry: XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V® EECSS) in the Treatment of the Specific Setting of Patients With Multi-vessel Coronary Artery Disease.

NCT01310309 is registered in ClinicalTrials.gov with Abbott Medical Devices as lead sponsor.

NCT NCT01310309
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01310309 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
EXecutive Registry: XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V® EECSS) in the Treatment of the Specific Setting of Patients With Multi-vessel Coronary Artery Disease.
Lead sponsor
Abbott Medical Devices
Phase
Observational
Overall status
Completed
Start date
September 30, 2007
Completion date
June 30, 2011
Enrollment
400 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

coronary artery disease, coronary artery restenosis, coronary artery stenosis, coronary disease